Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 137 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertrophic Cardiomyopathy Clear all
Active, not recruiting No phase listed Observational

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT06290570
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
12-Lead ECG, Apple Smart Watch Single Lead ECG, AliveCor KardiaMobile 6-Lead ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Extended ECG Monitoring in HCM Patients

NCT04056715
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation, Arrhythmia
Interventions
Zio XT
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease

NCT00027196
View directory record Official record
Conditions
Congenital Heart Defect
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
9,999,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

NCT00879060
View directory record Official record
Conditions
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting No phase listed Observational

Mavacamten Pregnancy Surveillance Program

NCT05939700
View directory record Official record
Conditions
Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older · Female only
Enrollment
20 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

NCT03496168
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Withdrawn No phase listed Observational

Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)

NCT00574821
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Oct 23, 2026, 1:21 AM EDT
Terminated No phase listed Observational

VIZ ACCESS HCM - Multi-Site Registry

NCT07103057
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM
Device
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Ninerafaxstat 200mg MR, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting Early Phase 1 Interventional

Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

NCT06433050
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy Without Obstruction
Interventions
Sotagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting No phase listed Observational

HCMR Re-Imaging Study

NCT07054073
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
None - observational study
Other
Lead sponsor
Christopher Kramer
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Medford, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Hypertrophic Cardiomyopathy Pilot Study

NCT02806479
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Coronary Artery Disease
Interventions
Observational: Arrhythmogenic Substrate
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

NCT07168655
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

NCT03043209
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Genetic Disease, Gene Product Sequence Variation
Interventions
Genomic sequencing
Genetic
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 23, 2026, 1:21 AM EDT
Not yet recruiting Not applicable Interventional

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

NCT07806149
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions
SESAME Procedure
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 23, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

NCT01736566
View directory record Official record
Conditions
Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
Interventions
Family History + Whole Genome Sequencing, Family History Only
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 23, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Large Language Models To Improve the Quality of Care of Cardiology Patients

NCT06935253
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Genetic Disease, Cardiology
Interventions
Large Language Model
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 23, 2026, 1:21 AM EDT
Completed No phase listed Observational

Viz HCM (ECG Assist) Utilization Workflow Pilot

NCT06600256
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Viz HCM ECG Review, Baseline Effectiveness Cohort
Behavioral
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
La Jolla, California • Ridgewood, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 1:21 AM EDT
Withdrawn Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

NCT01556568
View directory record Official record
Conditions
Cardiomegaly
Interventions
MEK162
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 23, 2026, 1:21 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 23, 2026, 1:21 AM EDT